Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
April 05, 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
March 30, 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022DANYELZA conditional marketing authorization granted in China...
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
March 21, 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December...
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
February 02, 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
January 04, 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million;Estimated total cash burn for 2023, including restructuring...
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
December 21, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe
December 16, 2022 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pipeline Update
December 14, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
December 08, 2022 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...